메뉴 건너뛰기




Volumn 72, Issue 7, 2009, Pages 621-626

B-type natriuretic peptide and cardiovalvulopathy in Parkinson disease with dopamine agonist

Author keywords

[No Author keywords available]

Indexed keywords

BRAIN NATRIURETIC PEPTIDE; CABERGOLINE; LEVODOPA; PERGOLIDE; BIOLOGICAL MARKER; DOPAMINE RECEPTOR STIMULATING AGENT;

EID: 61849172355     PISSN: 00283878     EISSN: 1526632X     Source Type: Journal    
DOI: 10.1212/01.wnl.0000342467.47860.f2     Document Type: Article
Times cited : (4)

References (39)
  • 1
    • 24344446871 scopus 로고    scopus 로고
    • Clinical practice: Diagnosis and initial management of Parkinson's disease
    • Nutt JG, Wooten GF. Clinical practice: diagnosis and initial management of Parkinson's disease. N Engl J Med 2005;353:1021-1027.
    • (2005) N Engl J Med , vol.353 , pp. 1021-1027
    • Nutt, J.G.1    Wooten, G.F.2
  • 2
    • 34547828793 scopus 로고    scopus 로고
    • Fibrotic heart-valve reactions to dopamine-agonist treatment in Parkinson's disease
    • Antonini A, Poewe W. Fibrotic heart-valve reactions to dopamine-agonist treatment in Parkinson's disease. Lancet Neurol 2007;6:826-829.
    • (2007) Lancet Neurol , vol.6 , pp. 826-829
    • Antonini, A.1    Poewe, W.2
  • 3
    • 37149051357 scopus 로고    scopus 로고
    • Heart valve regurgitation, pergolide use, and Parkinson disease: An observational study and meta-analysis
    • Corvol JC, Anzouan-Kacou JB, Fauveau E, et al. Heart valve regurgitation, pergolide use, and Parkinson disease: an observational study and meta-analysis. Arch Neurol 2007;64:1721-1726.
    • (2007) Arch Neurol , vol.64 , pp. 1721-1726
    • Corvol, J.C.1    Anzouan-Kacou, J.B.2    Fauveau, E.3
  • 4
    • 36348942365 scopus 로고    scopus 로고
    • Low incidence of restrictive valvulopathy in patients with Parkinson's disease on moderate dose of pergolide
    • Růzicka E, Linková H, Penicka M, Ulmanová O, Nová-ková L, Roth J. Low incidence of restrictive valvulopathy in patients with Parkinson's disease on moderate dose of pergolide. J Neurol 2007;254:1575-1578.
    • (2007) J Neurol , vol.254 , pp. 1575-1578
    • Růzicka, E.1    Linková, H.2    Penicka, M.3    Ulmanová, O.4    Nová-ková, L.5    Roth, J.6
  • 5
    • 33947196215 scopus 로고    scopus 로고
    • Cardiac valve regurgitation with pergolide compared with nonergot agonists in Parkinson disease
    • Dewey RB 2nd, Reimold SC, O'Suilleabhain PE. Cardiac valve regurgitation with pergolide compared with nonergot agonists in Parkinson disease. Arch Neurol 2007;64: 377-380.
    • (2007) Arch Neurol , vol.64 , pp. 377-380
    • Dewey 2nd, R.B.1    Reimold, S.C.2    O'Suilleabhain, P.E.3
  • 8
    • 33847759919 scopus 로고    scopus 로고
    • Valvular heart disease in Parkinson's disease patients treated with dopamine agonists: A reader-blinded monocenter echocar-diography study
    • Junghanns S, Fuhrmann JT, Simonis G, et al. Valvular heart disease in Parkinson's disease patients treated with dopamine agonists: a reader-blinded monocenter echocar-diography study. Mov Disord 2007;22:234-238.
    • (2007) Mov Disord , vol.22 , pp. 234-238
    • Junghanns, S.1    Fuhrmann, J.T.2    Simonis, G.3
  • 9
    • 33749865531 scopus 로고    scopus 로고
    • Dopamine agonists and cardiac valvulopathy in Parkinson disease: A case-control study
    • Yamamoto M, Uesugi T, Nakayama T. Dopamine agonists and cardiac valvulopathy in Parkinson disease: a case-control study. Neurology 2006;67:1225-1229.
    • (2006) Neurology , vol.67 , pp. 1225-1229
    • Yamamoto, M.1    Uesugi, T.2    Nakayama, T.3
  • 10
    • 33748363728 scopus 로고    scopus 로고
    • Valvular heart disease in Parkinson's disease treated with ergot derivative dopamine agonists
    • Kim JY, Chung EJ, Park SW, Lee WY. Valvular heart disease in Parkinson's disease treated with ergot derivative dopamine agonists. Mov Disord 2006;21:1261-1264.
    • (2006) Mov Disord , vol.21 , pp. 1261-1264
    • Kim, J.Y.1    Chung, E.J.2    Park, S.W.3    Lee, W.Y.4
  • 11
    • 33748311590 scopus 로고    scopus 로고
    • Valvular heart disease in Parkinson's disease vs. controls: An echocardiographic study
    • Peralta C, Wolf E, Alber H, et al. Valvular heart disease in Parkinson's disease vs. controls: An echocardiographic study. Mov Disord 2006;21:1109-1113.
    • (2006) Mov Disord , vol.21 , pp. 1109-1113
    • Peralta, C.1    Wolf, E.2    Alber, H.3
  • 12
    • 23244443740 scopus 로고    scopus 로고
    • Valvular heart disease in patients taking pergolide
    • Waller EA, Kaplan J, Heckman MG. Valvular heart disease in patients taking pergolide. Mayo Clin Proc 2005;80: 1016-1020.
    • (2005) Mayo Clin Proc , vol.80 , pp. 1016-1020
    • Waller, E.A.1    Kaplan, J.2    Heckman, M.G.3
  • 14
    • 4444351812 scopus 로고    scopus 로고
    • Severe mul-tivalvular heart disease: A new complication of the ergot derivative dopamine agonists
    • Horvath J, Fross RD, Kleiner-Fisman G, et al. Severe mul-tivalvular heart disease: a new complication of the ergot derivative dopamine agonists. Mov Disord 2004;19:656-662.
    • (2004) Mov Disord , vol.19 , pp. 656-662
    • Horvath, J.1    Fross, R.D.2    Kleiner-Fisman, G.3
  • 15
    • 11144354035 scopus 로고    scopus 로고
    • Treatment of Parkinson's disease with pergolide and relation to restrictive valvular heart disease
    • Van Camp G, Flamez A, Cosyns B, et al. Treatment of Parkinson's disease with pergolide and relation to restrictive valvular heart disease. Lancet 2004;363:1179-1183.
    • (2004) Lancet , vol.363 , pp. 1179-1183
    • Van Camp, G.1    Flamez, A.2    Cosyns, B.3
  • 16
    • 0141653014 scopus 로고    scopus 로고
    • Heart valvular disease in patients with Parkinson's disease treated with high-dose pergolide
    • Van Camp G, Flamez A, Cosyns B, Goldstein J, Perdaens C, Schoors D. Heart valvular disease in patients with Parkinson's disease treated with high-dose pergolide. Neurology 2003;61:859-861.
    • (2003) Neurology , vol.61 , pp. 859-861
    • Van Camp, G.1    Flamez, A.2    Cosyns, B.3    Goldstein, J.4    Perdaens, C.5    Schoors, D.6
  • 18
    • 0038581961 scopus 로고    scopus 로고
    • The US Food and Drug Administration's registry of patients with pergolide-associated valvular heart disease
    • Flowers CM, Racoosin JA, Lu SL, Beitz JG. The US Food and Drug Administration's registry of patients with pergolide-associated valvular heart disease. Mayo Clin Proc 2003:78:730-731.
    • (2003) Mayo Clin Proc , vol.78 , pp. 730-731
    • Flowers, C.M.1    Racoosin, J.A.2    Lu, S.L.3    Beitz, J.G.4
  • 19
    • 33744457002 scopus 로고    scopus 로고
    • Role of B-type natriuretic peptide (BNP) and NT-proBNP in clinical routine
    • Weber M, Hamm C. Role of B-type natriuretic peptide (BNP) and NT-proBNP in clinical routine. Heart 2006; 92:843-849.
    • (2006) Heart , vol.92 , pp. 843-849
    • Weber, M.1    Hamm, C.2
  • 20
    • 33645071970 scopus 로고    scopus 로고
    • Association of B-type natriuretic peptide activation to left ventricular end-systolic remodeling in organic and functional mitral regurgitation
    • Detaint D, Messika-Zeitoun D, Chen HH, et al. Association of B-type natriuretic peptide activation to left ventricular end-systolic remodeling in organic and functional mitral regurgitation. Am J Cardiol 2006;97:1029-1034.
    • (2006) Am J Cardiol , vol.97 , pp. 1029-1034
    • Detaint, D.1    Messika-Zeitoun, D.2    Chen, H.H.3
  • 21
    • 4444340383 scopus 로고    scopus 로고
    • Elevated B-type natriuretic peptide in asymptomatic men with chronic aortic regurgitation and preserved left ventricular systolic function
    • Eimer MJ, Ekery DL, Rigolin VH, Bonow RO, Carne-thon MR, Cotts WG. Elevated B-type natriuretic peptide in asymptomatic men with chronic aortic regurgitation and preserved left ventricular systolic function. Am J Cardiol 2004;94:676-678.
    • (2004) Am J Cardiol , vol.94 , pp. 676-678
    • Eimer, M.J.1    Ekery, D.L.2    Rigolin, V.H.3    Bonow, R.O.4    Carne-thon, M.R.5    Cotts, W.G.6
  • 22
    • 67650454167 scopus 로고    scopus 로고
    • Relationship between non-motor function and quality of life in Parkinson's disease; longitudinal study
    • Abstract
    • Watanabe H, Atsuta N, Ito M, et al. Relationship between non-motor function and quality of life in Parkinson's disease; longitudinal study. Rinsho Shinkeigaku 2007:47: 1015. Abstract.
    • (2007) Rinsho Shinkeigaku , vol.47 , pp. 1015
    • Watanabe, H.1    Atsuta, N.2    Ito, M.3
  • 23
    • 0026695663 scopus 로고
    • Criteria for diagnosing Parkinson's disease
    • Calne DB, Snow BJ, Lee C. Criteria for diagnosing Parkinson's disease. Ann Neurol 1992;32:S125-S127.
    • (1992) Ann Neurol , vol.32
    • Calne, D.B.1    Snow, B.J.2    Lee, C.3
  • 24
    • 5644220292 scopus 로고    scopus 로고
    • Switching and combining of dopamine agonists
    • VI/19-23
    • Junghanns S, Glöckler T, Reichmann H. Switching and combining of dopamine agonists. J Neurol 2004;251 suppl 6:VI/19-23.
    • (2004) J Neurol , Issue.SUPPL. 6 , pp. 251
    • Junghanns, S.1    Glöckler, T.2    Reichmann, H.3
  • 25
    • 0036827811 scopus 로고    scopus 로고
    • Differential actions of antiparkinson agents at multiple classes of monoaminergic receptor: I: a multivariate analysis of the binding profiles of 14 drugs at 21 native and cloned human receptor subtypes
    • Millan MJ, Maiofiss L, Cussac D, et al. Differential actions of antiparkinson agents at multiple classes of monoaminergic receptor: I: a multivariate analysis of the binding profiles of 14 drugs at 21 native and cloned human receptor subtypes. J Pharmacol Exp Ther 2002:303:791-804.
    • (2002) J Pharmacol Exp Ther , vol.303 , pp. 791-804
    • Millan, M.J.1    Maiofiss, L.2    Cussac, D.3
  • 26
    • 18144416218 scopus 로고    scopus 로고
    • Agonism at 5-HT2b receptor is not a class effect of the ergolines
    • Jahnichen S, Horowski R, Pertz HH. Agonism at 5-HT2b receptor is not a class effect of the ergolines. Eur J Pharmacol 2005:513:225-229.
    • (2005) Eur J Pharmacol , vol.513 , pp. 225-229
    • Jahnichen, S.1    Horowski, R.2    Pertz, H.H.3
  • 27
    • 0142008980 scopus 로고    scopus 로고
    • Recommendations for evaluation of the severity of native valvular regurgitation with two-dimensional and Doppler echocar-diography
    • Zoghbi WA, Enriquez-Sarano M, Foster E, et al. Recommendations for evaluation of the severity of native valvular regurgitation with two-dimensional and Doppler echocar-diography. J Am Soc Echocardiogr 2003:16:777-802.
    • (2003) J Am Soc Echocardiogr , vol.16 , pp. 777-802
    • Zoghbi, W.A.1    Enriquez-Sarano, M.2    Foster, E.3
  • 28
    • 0015237841 scopus 로고
    • The natural history of congestive heart failure: The Framingham study
    • McKee PA, Castelli WP, McNamara PM, et al. The natural history of congestive heart failure: the Framingham study. N Engl J Med 1971;285:1441-1446.
    • (1971) N Engl J Med , vol.285 , pp. 1441-1446
    • McKee, P.A.1    Castelli, W.P.2    McNamara, P.M.3
  • 29
    • 0027210870 scopus 로고
    • Survival after the onset of congestive heart failure in Framingham Heart Study subjects
    • Ho KK, Anderson KM, Kannel WB, et al. Survival after the onset of congestive heart failure in Framingham Heart Study subjects. Circulation 1993:88:107-115.
    • (1993) Circulation , vol.88 , pp. 107-115
    • Ho, K.K.1    Anderson, K.M.2    Kannel, W.B.3
  • 30
    • 34948817624 scopus 로고    scopus 로고
    • In vivo model of drug-induced valvular heart disease in rats: Pergolide-induced valvular heart disease demonstrated with echocar-diography and correlation with pathology
    • Droogmans S, Franken PR, Garbar C, et al. In vivo model of drug-induced valvular heart disease in rats: pergolide-induced valvular heart disease demonstrated with echocar-diography and correlation with pathology. Eur Heart J 2007:28:2156-2162.
    • (2007) Eur Heart J , vol.28 , pp. 2156-2162
    • Droogmans, S.1    Franken, P.R.2    Garbar, C.3
  • 31
    • 0031734994 scopus 로고    scopus 로고
    • Plasma B-type natriuretic peptide measurement in a multiphasic health screening program
    • Niinuma H, Nakamura M, Hiramori K. Plasma B-type natriuretic peptide measurement in a multiphasic health screening program. Cardiology 1998:90:89-94.
    • (1998) Cardiology , vol.90 , pp. 89-94
    • Niinuma, H.1    Nakamura, M.2    Hiramori, K.3
  • 32
    • 0036153284 scopus 로고    scopus 로고
    • Value of plasma B type natriuretic peptide measurement for heart disease screening in a Japanese population
    • Nakamura M, Endo H, Nasu M, Arakawa N, Segawa T, Hiramori K. Value of plasma B type natriuretic peptide measurement for heart disease screening in a Japanese population. Heart 2002:87:131-135.
    • (2002) Heart , vol.87 , pp. 131-135
    • Nakamura, M.1    Endo, H.2    Nasu, M.3    Arakawa, N.4    Segawa, T.5    Hiramori, K.6
  • 34
    • 2342572869 scopus 로고    scopus 로고
    • Greater change of orthostatic blood pressure is related to silent cerebral in-farct and cardiac overload in hypertensive subjects
    • Eguchi K, Kario K, Hoshide S, et al. Greater change of orthostatic blood pressure is related to silent cerebral in-farct and cardiac overload in hypertensive subjects. Hyper-tens Res 2004:27:235-241.
    • (2004) Hyper-tens Res , vol.27 , pp. 235-241
    • Eguchi, K.1    Kario, K.2    Hoshide, S.3
  • 35
    • 0038779278 scopus 로고    scopus 로고
    • 3,4- Methylenedioxymethamphetamine (MDMA, "Ecstasy") induces fenfluramine-like proliferative actions on human cardiac valvular interstitial cells in vitro
    • Setola V, Hufeisen SJ, Grande-Allen KJ, et al. 3,4- Methylenedioxymethamphetamine (MDMA, "Ecstasy") induces fenfluramine-like proliferative actions on human cardiac valvular interstitial cells in vitro. Mol Pharmacol 2003:63:1223-1229.
    • (2003) Mol Pharmacol , vol.63 , pp. 1223-1229
    • Setola, V.1    Hufeisen, S.J.2    Grande-Allen, K.J.3
  • 36
    • 0036828154 scopus 로고    scopus 로고
    • Differential actions of antiparkinson agents at multiple classes of monoaminergic receptor. III. Agonist and antagonist properties at serotonin, 5-HT(1) and 5-HT(2), receptor subtypes
    • Newman-Tancredi A, Cussac D, Quen-tric Y, et al. Differential actions of antiparkinson agents at multiple classes of monoaminergic receptor. III. Agonist and antagonist properties at serotonin, 5-HT(1) and 5-HT(2), receptor subtypes. J Pharmacol Exp Ther 2002:303:815-822.
    • (2002) J Pharmacol Exp Ther , vol.303 , pp. 815-822
    • Newman-Tancredi, A.1    Cussac, D.2    Quen-tric, Y.3
  • 37
    • 33748286837 scopus 로고    scopus 로고
    • Ergoline and non-ergoline derivatives in the treatment of Parkinson's disease
    • Reichmann H, Bilsing A, Ehret R, et al. Ergoline and non-ergoline derivatives in the treatment of Parkinson's disease. J Neurol 2006:253 suppl 4:iv36-iv38.
    • (2006) J Neurol , vol.253 , Issue.SUPPL. 4
    • Reichmann, H.1    Bilsing, A.2    Ehret, R.3
  • 38
    • 34547609651 scopus 로고    scopus 로고
    • Serial biomarker measurements in ambulatory patients with chronic heart failure: The importance of change over time
    • Miller WL, Hartman KA, Burritt MF, et al. Serial biomarker measurements in ambulatory patients with chronic heart failure: the importance of change over time. Circulation 2007:116:249-257.
    • (2007) Circulation , vol.116 , pp. 249-257
    • Miller, W.L.1    Hartman, K.A.2    Burritt, M.F.3
  • 39
    • 18444414911 scopus 로고    scopus 로고
    • B-type natriuretic peptide in organic mitral regurgitation: Determinants and impact on outcome
    • Detaint D, Messika-Zeitoun D, Avierinos JF, et al. B-type natriuretic peptide in organic mitral regurgitation: determinants and impact on outcome. Circulation 2005:111: 2391-2397.
    • (2005) Circulation , vol.111 , pp. 2391-2397
    • Detaint, D.1    Messika-Zeitoun, D.2    Avierinos, J.F.3


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.